Twist Bioscience Co. (NASDAQ:TWST) COO Sells $140,400.75 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,845 shares of Twist Bioscience stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $140,400.75. Following the completion of the transaction, the chief operating officer now owns 269,199 shares in the company, valued at approximately $13,284,970.65. This represents a 1.05 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Patrick John Finn also recently made the following trade(s):

• On Thursday, January 23rd, Patrick John Finn sold 2,422 shares of Twist Bioscience stock. The shares were sold at an average price of $50.17, for a total transaction of $121,511.74.
• On Friday, January 3rd, Patrick John Finn sold 229 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total transaction of $10,440.11.
• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total value of $496,320.00.

Twist Bioscience Trading Up 3.2 %

Shares of TWST traded up $1.64 during midday trading on Wednesday, reaching $53.66. 942,522 shares of the company were exchanged, compared to its average volume of 780,335. The company has a market cap of $3.19 billion, a price-to-earnings ratio of -14.91 and a beta of 1.87. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The stock has a 50-day moving average price of $48.63 and a 200-day moving average price of $46.21.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. The company had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. During the same period in the previous year, the business earned ($0.75) EPS. The company’s revenue was up 24.1% on a year-over-year basis. Equities research analysts anticipate that Twist Bioscience Co. will post -2.27 earnings per share for the current year.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors have recently added to or reduced their stakes in the company. Thrivent Financial for Lutherans acquired a new position in shares of Twist Bioscience in the 3rd quarter valued at $43,992,000. State Street Corp lifted its position in Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after buying an additional 526,028 shares in the last quarter. Wellington Management Group LLP lifted its position in Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after buying an additional 521,272 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Twist Bioscience by 80.2% in the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock valued at $31,636,000 after purchasing an additional 302,884 shares during the period. Finally, ARK Investment Management LLC raised its holdings in shares of Twist Bioscience by 4.4% in the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock valued at $260,040,000 after purchasing an additional 237,772 shares during the period.

Analysts Set New Price Targets

A number of brokerages recently weighed in on TWST. Barclays dropped their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 19th. Scotiabank lifted their price target on Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a research report on Tuesday. Robert W. Baird boosted their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday. JPMorgan Chase & Co. lifted their price target on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research note on Tuesday. Finally, TD Cowen reissued a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.